Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus
NCT05360147 on ClinicalTrials.gov · last registry update 2022-05-04
A small phase 3 — 30 participants, against a typical 424. The sponsor logged completion for 20 April 2021. Primary outcome, as filed: Changes in cognitive function from baseline to 12 weeks. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Third Military Medical University
- Sponsor type
- Other
- Enrollment
- 30
- Started
- 2021-01-20
- Primary completion
- 2021-04-20 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Changes in cognitive function from baseline to 12 weeks
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.